The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells
Johannes Kraus(Kantonsspital St. Gallen), Christoph Driessen(University of Zurich)
Cited by 21
Related Papers
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
|The Lancet Oncology|2021|266
Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis
|Molecular Cancer Therapeutics|2008|67